Lloyd R. Kèlland
#133,774
Most Influential Person Now
Lloyd R. Kèlland's AcademicInfluence.com Rankings
Lloyd R. Kèllandchemistry Degrees
Chemistry
#3204
World Rank
#4201
Historical Rank
Inorganic Chemistry
#150
World Rank
#162
Historical Rank
Organic Chemistry
#504
World Rank
#583
Historical Rank
Lloyd R. Kèllandbiology Degrees
Biology
#9003
World Rank
#12157
Historical Rank
Biochemistry
#1341
World Rank
#1462
Historical Rank
Download Badge
Chemistry Biology
Lloyd R. Kèlland's Degrees
- PhD Chemistry Stanford University
- Bachelors Chemistry University of California, Berkeley
Why Is Lloyd R. Kèlland Influential?
(Suggest an Edit or Addition)Lloyd R. Kèlland's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The resurgence of platinum-based cancer chemotherapy (2007) (3821)
- Short tandem repeat profiling provides an international reference standard for human cell lines (2001) (427)
- Discovery and development of anticancer aptamers (2006) (414)
- Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors (2001) (402)
- Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. (2007) (364)
- DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. (1999) (357)
- Platinum-Based Drugs in Cancer Therapy (2000) (306)
- Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. (2004) (284)
- The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. (1991) (264)
- A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. (2002) (260)
- Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. (2005) (239)
- Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. (1993) (228)
- New platinum antitumor complexes. (1993) (226)
- A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. (2001) (213)
- Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. (2003) (196)
- Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. (1989) (186)
- Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. (1999) (182)
- In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. (1998) (179)
- Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. (2001) (173)
- Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. (1992) (168)
- Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. (2003) (166)
- Preclinical Perspectives on Platinum Resistance (2012) (164)
- Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models (2005) (163)
- Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. (1991) (159)
- Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. (1992) (158)
- BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. (2000) (156)
- Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. (1996) (155)
- A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. (2004) (153)
- Targeting the Limitless Replicative Potential of Cancer: The Telomerase/Telomere Pathway (2007) (139)
- A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo (2010) (136)
- DNA Repair capacity and cisplatin sensitivity of human testis tumour cells (1997) (133)
- Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status (2000) (133)
- In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202 (2005) (129)
- A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. (1994) (127)
- cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. (1997) (115)
- Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. (1992) (115)
- Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. (2000) (114)
- SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity (2004) (113)
- Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. (2001) (112)
- Induction of apoptosis by a novel copper-based anticancer compound, casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells. (2000) (112)
- Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. (2005) (109)
- Signal transduction pathways. (1998) (107)
- Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. (1995) (107)
- In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. (1993) (107)
- Biotransformation of the platinum drug JM216 following oral administration to cancer patients (1996) (106)
- BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma (2000) (104)
- Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma. (1999) (102)
- Broadening the clinical use of platinum drug–based chemotherapy with new analogues (2007) (102)
- Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. (2002) (101)
- Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. (1992) (99)
- Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). (1998) (93)
- Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. (1997) (90)
- Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 (2005) (90)
- Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. (1992) (86)
- An update on satraplatin: the first orally available platinum anticancer drug (2000) (78)
- Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines (2004) (75)
- Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. (1995) (74)
- Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. (2000) (70)
- Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability (2005) (70)
- Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding. (2004) (70)
- Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines. (1999) (68)
- DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines (1995) (68)
- Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. (2000) (66)
- Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo. (1998) (65)
- In vitro and in vivo antitumor activity of benzyl isothiocyanate: a natural product from Tropaeolum majus. (1995) (63)
- Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. (1995) (60)
- Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents. (2007) (59)
- Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)]. (2003) (58)
- The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. (1990) (58)
- ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. (2002) (58)
- A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration (2004) (57)
- Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay (1996) (54)
- New Developments and Approaches in the Platinum Arena (2012) (54)
- Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system. (1999) (52)
- Synthesis, characterization, and cytotoxicity of trifunctional dinuclear platinum complexes: comparison of effects of geometry and polyfunctionality on biological activity. (2000) (51)
- 2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships. (1999) (51)
- Telomerase: biology and phase I trials. (2001) (50)
- Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. (1992) (50)
- Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. (1994) (50)
- Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment (2005) (49)
- Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. (2002) (49)
- Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. (2005) (47)
- Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. (1995) (45)
- Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. (1998) (44)
- Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells (2010) (43)
- Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin (1999) (43)
- In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. (1994) (42)
- Synthesis and Reactions of a New Class of Orally Active Pt(IV) Antitumor Complexes (1991) (41)
- Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. (2006) (41)
- Telomerase inhibitors: targeting the vulnerable end of cancer? (2000) (41)
- Synthesis of a novel C2/C2′-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity (1999) (41)
- Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. (2002) (41)
- Symmetric bis-benzimidazoles: new sequence-selective DNA-binding molecules (1999) (41)
- Farnesyl transferase inhibitors--a novel therapy for breast cancer. (2001) (41)
- cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines (2009) (41)
- Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. (1995) (39)
- A Synthetic Azinomycin Analogue with Demonstrated DNA Cross‐Linking Activity: Insights into the Mechanism of Action of this Class of Antitumor Agent (2000) (39)
- Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET (2000) (39)
- Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. (1996) (38)
- Analysis of human papillomavirus sequences in cell lines recently derived from cervical cancers. (1988) (36)
- G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. (2009) (36)
- Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian‐carcinoma cell lines (1993) (36)
- Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. (2003) (36)
- Variation in RNA expression and genomic DNA content acquired during cell culture (2004) (35)
- Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines. (1994) (35)
- The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. (1993) (35)
- Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates. (2001) (35)
- Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy (2005) (33)
- In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. (2001) (33)
- Farnesyl transferase inhibitors in the treatment of breast cancer (2003) (33)
- Cytotoxicity of bis(phenylamidinium)furan alkyl derivatives in human tumour cell lines: Relation to DNA minor groove binding (1997) (32)
- Ammine/Amine Platinum IV Dicarboxylates: A Novel Class of Complexes Which Circumvent Intrinsic Cisplatin Resistance (1991) (31)
- Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. (1996) (31)
- Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. (2011) (31)
- Discontinued drugs in 2005: oncology drugs (2006) (31)
- Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. (2003) (31)
- Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991. (1991) (30)
- Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. (1996) (30)
- Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines (2000) (30)
- High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance (2001) (30)
- Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Crystal and molecular structure of [PtL4CL2].H20 where L4 is ethylenediamine-N,N'-diacetate. (2001) (30)
- Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. (2001) (30)
- Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity. (2008) (30)
- Genomic imbalances associated with acquired resistance to platinum analogues. (1999) (30)
- 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) (2006) (29)
- 1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation. (1997) (29)
- Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. (1994) (29)
- Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex. (1996) (28)
- Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. (2007) (28)
- Characterisation of the P53 status, BCL‐2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines (1998) (27)
- Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. (1994) (27)
- Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery (2004) (27)
- Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. (1993) (24)
- Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. (1995) (23)
- Non-surgical aspects of ovarian cancer Report of a Meeting of Physicians and Scientists, Institute of Cancer Research and the Royal Marsden Hospital, London (1994) (22)
- Telomeres and telomerase: targets for cancer chemotherapy? (1998) (22)
- Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120 (1996) (22)
- Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. (2002) (21)
- Cisplatin-DNA damage recognition proteins in human tumour extracts. (1993) (21)
- Platinum coordination complexes which circumvent cisplatin resistance. (1991) (21)
- ras mutation and platinum resistance in human ovarian carcinomas in vitro (1998) (20)
- Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. (1999) (19)
- Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. (1999) (19)
- Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer. (2001) (19)
- Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines. (2000) (19)
- Overexpression of BclXL in a human ovarian carcinoma cell line: Paradoxic effects on chemosensitivity in vitro versus in vivo (2002) (18)
- Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2007) (18)
- In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine , Bohemine and CYC 202 (2005) (17)
- New Platinum Agents (1994) (17)
- Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B (2004) (16)
- Overcoming Resistance to Platinum Therapy in Patients with Advanced Cancer (2002) (16)
- The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study. (1996) (16)
- Emerging drugs for ovarian cancer (2005) (15)
- The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. (1994) (15)
- Synthesis, cytotoxicity and DNA cross-linking activityof symmetrical dimers based upon the epoxide domain of the azinomycins (2000) (15)
- Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit. (2000) (15)
- Bioreductive prodrugs for cancer therapy. (2004) (14)
- Effect of p 53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line (2000) (14)
- N4-(ω-Aminoalkyl)-1-[(ω-aminoalkyl)amino]-4-acridinecarboxamides: Novel, Potent, Cytotoxic, and DNA-Binding Agents (2000) (14)
- A New Ring-Forming Methodology for the Synthesis of Bioactive Pyrroloquinoline Derivatives (2002) (13)
- Synthesis and reactivity of some chiral, nonracemic 1-azabicyclo[4.1.0]heptanes related to the azinomycins (1998) (13)
- New Platinum Drugs (1993) (13)
- Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. (2007) (12)
- Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells. (2004) (11)
- Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. (1994) (11)
- A new resistance mechanism to cisplatin? (2000) (11)
- The Development of Orally Active Platinum Drugs (2006) (10)
- Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. (1999) (10)
- The measurement of deoxynucleotide (dNTP) pools by radioimmunoassay (RIA). (1994) (10)
- Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum[II]) (2000) (9)
- New platinum agents. A comparison in ovarian cancer. (1994) (9)
- New Platinum Drugs: The Pathway to Oral Therapy (2000) (8)
- Antitumor-activity of orally-administered ammine amine platinum (iv) dicarboxylate complexes against a panel of human ovarian-carcinoma xenografts. (1993) (8)
- 1-[(ω-Aminoalkyl)amino]-4- [N-(ω-aminoalkyl)carbamoyl]-9-oxo-9,10-dihydroacridines as Intercalating Cytotoxic Agents: Synthesis, DNA Binding, and Biological Evaluation. (1998) (7)
- Effect of C2-exo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines. (2000) (7)
- 414A Pharmacological properties and in vitro and in vivo antitumour activity of the potent and selective PI3 kinase inhibitor PI103 (2004) (7)
- Novel imidazothioxanthones: Synthesis, DNA binding and cytotoxicity (1996) (6)
- Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel Trans platinum complex, JM335 [Trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)] (1994) (6)
- Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. (2005) (6)
- An expeditious synthesis of cytotoxic pyrroloisoquinoline derivatives. Structure-activity comparative studies with isomeric pyrroloquinolines. (2002) (6)
- Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors. (1996) (6)
- Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug. (2002) (5)
- Platinum anticancer drugs (1994) (5)
- Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo. (2004) (5)
- Synthesis of a Novel C2/C2′‐exo Unsaturated Pyrrolobenzodiazepine Cross‐Linking Agent with Remarkable DNA Binding Affinity and Cytotoxicity. (1999) (5)
- Cyclin-Dependent Kinase Inhibitors and Combination Therapy: Experimental and Clinical Status (2006) (5)
- Development of an Orally Active Platinum Anticancer Drug: JM216 (1999) (5)
- Novel platinum(II) derivatives of analogues of netropsin and distamycin: Synthesis, DNA binding and cytotoxic properties (1996) (5)
- Ammine/amine platinum (IV) dicarboxylates: A lead to the discovery of a new generation of broad spectrum platinum-based anticancer drugs (1993) (5)
- Design, Synthesis, and Evaluation of a Novel Pyrrolobenzodiazepine DNA‐Interactive Agent with Highly Efficient Cross‐Linking Ability and Potent Cytotoxicity. (2001) (5)
- Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore. (2003) (4)
- Section Review: Oncologic, Endocrine & Metabolic: Platinum agents in the treatment of cancer (1996) (4)
- Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. (2003) (4)
- Plasma levels of 5-hydroxyindole-3-acetic acid (5HIAA) as a pharmacodynamic marker of blood flow changes induced by the vascular targeting agent (VTA) 5,6 dimethyl xanthenone acetic acid, DMXAA (2005) (4)
- Small molecule anticancer drugs. (1999) (4)
- N-cadherin: A novel target for cancer therapy? (2007) (4)
- Synthesis of new bifunctional compounds which selectively alkylate guanines in DNA. (1998) (4)
- Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol. (2006) (4)
- Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol. (2000) (4)
- Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen. (2001) (4)
- Synthesis of the First Example of a C2-C3/C2′-C3′-endo Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine Dimer. (2002) (3)
- DNA Repair Enzymes and Platinum Drug Resistance in Tumors (2008) (3)
- Copper-64-diphosphine complexes: Potential PET tracers for the assessment of multi-drug resistance in tumors (1997) (3)
- Symmetric bis-benzimidazoles, a new class of sequence-selective DNA-binding molecules (2000) (3)
- Cisplatin and analogues. (2001) (3)
- A New Class of Symmetric Bisbenzimidazole‐Based DNA Minor Groove‐Binding Agents Showing Antitumor Activity. (2001) (3)
- N4‐(ω‐Aminoalkyl)‐1‐ [(ω‐aminoalkyl)amino]‐4‐acridinecarboxamides: Novel, Potent, Cytotoxic, and DNA‐Binding Agents. (2001) (2)
- 149 Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2004) (2)
- Synthesis, Cytotoxicity and DNA Cross-Linking Activity of Symmetrical Dimers Based Upon the Epoxide Domain of the Azinomycins. (2001) (2)
- Endocrine-Related Cancer ( 2001 ) 8 227 – 235 Farnesyl transferase inhibitors – a novel therapy for breast cancer (2001) (1)
- Advances in Brief BBR 3464 : A Novel Triplatinum Complex , Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin 1 (2000) (1)
- Preclinical pharmacology of 1069C85, a novel tubulin binder (2004) (1)
- Telomere Targeting Agents (2006) (1)
- 981 The development of new platinum complexes: Oral delivery and non-cross resistance (1995) (1)
- Cancer cell kill, in vivo biodistribution and antitumor properties of AS1411, a G-rich oligonucleotide aptamer (2006) (1)
- Preclinical pharmacology and in vivo models (2008) (1)
- Modulation of drug resistance in paediatric rhabdomyosarcoma. (1999) (1)
- Novel Imidazothioxanthones: Synthesis, DNA Binding and Cytotoxicity. (1996) (1)
- Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R 115777 in a Human Colon Cancer Cell Line 1 (2002) (1)
- Oncogene-Directed Therapies (2003) (0)
- The author's response (2008) (0)
- PRECLINICAL TESTING AND VALIDATION OF NOVEL ANTICANCER AGENTS (2006) (0)
- Changes in apoptosis-related protein expression in acquired paclitaxel resistant human ovarian cancer in-vivo. (2001) (0)
- Synthesis and Reactivity of Some Chiral, Nonracemic 1-Azabicyclo[4.1.0]heptanes Related to the Azinomycins. (1998) (0)
- NCI-EORTC--10th Symposium--new approaches and cellular targets. 16-19 June 1998, Amsterdam, The Netherlands. (1998) (0)
- DNA-interactive agents. (1998) (0)
- PRIMARY CELL CULTURES FROM OVARIAN CANCER PATIENTS TO DETERMINE ASPECTS OF DRUG RESISTANCE (2004) (0)
- Tumor dose response to 5,6-dimethylxanthenone-4-acetic acid (DMXAA) assessed by in vivo magnetic resonance spectroscopy (2004) (0)
- Low dose rate radiobiology of human tumor cells (1986) (0)
- 545 Biological effects of G-Quadruplex binding agents in various human cancer cell lines (2004) (0)
- 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'-SYMMETRIC BIS-BENZIMIDAZOLE COMPLEX (2001) (0)
- Small molecule inhibitors of protein kinase D inhibit cancer cell growth through inhibition of growth factor-stimulated proliferation and induction of apoptosis. (2007) (0)
- Bcl-2 family immunohistochemistry. (1999) (0)
- Synthesis and Biological Evaluation of an N10‐Psec Substituted Pyrrolo[2,1‐c][1,4]benzodiazepine Prodrug. (2002) (0)
- N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents. (2000) (0)
- 454 INVITED Telomere targeting agents - clinical development candidates (2006) (0)
- New Perfluorophtalate Complexes of Platinum(II) With Chemotherapeutic Potential (1996) (0)
- 34. Copper diphosphine complexes: Potential agents for PET evaluation of multidrug resistance of tumours in vivo (1997) (0)
- Book review (2004) (0)
- High throughput screen for inhibitors of protein kinase C iota (PKCι) (2007) (0)
- Thioplatin A sulfur-containing platinum complex possessing greater activity in acidic pH, non-cross resistance with cisplatin and antitumor activity in vivo (2002) (0)
- Combination of chemotherapy and radioimmunotherapy using 90Y-labelled anti-MUC1 humanized monoclonal antibody in a human tumor xenograft model. (2004) (0)
- Establishment and Characterization of an in Vitro Model of Acquired Resistance to Cisplatin in a Human Testicular Nonseminomatous Germ Cell Line1 (2006) (0)
- Symmetric Bis‐benzimidazoles: New Sequence‐Selective DNA‐Binding Molecules. (1999) (0)
- Preclinical anticancer properties of potent small molecule inhibitors of protein kinase D (2007) (0)
- Small molecule inhibitors of the transmembrane receptor tyrosine kinase Axl as anticancer therapeutics (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Lloyd R. Kèlland?
Lloyd R. Kèlland is affiliated with the following schools:
